Buscar Close Search
Buscar Close Search

Developing Breakthrough RNA Therapeutics

By interweaving nucleic acid scientists with clinicians dedicated to finding new cures, our goal is to create a new paradigm for organizing molecular research that enables the rapid application of new biological discoveries to solutions for unmet challenges in human health.

 LILI.png

RTI Spotlight  

BRIDGE Innovation and Business Development at UMass Chan Medical School has committed nearly $2 million in funding this year for six UMass Chan Medical School investigator-led research projects that hold promise for translation to clinical application and commercialization. Dr. Li Li, assistant professor of RNA Therapeutics, was selected as a recipient for his project, Developing nucleoside-modified circular mRNAs as a durable and non-immunogenic platform for mRNA therapeutics.  Read more»

 2025 crop_card.png

2025 RNA Therapeutics: From Concept to Clinic


Save the dates
for our 7th annual RNA Therapeutics Symposium, June 25-27, 2025!


Abstract submission
is OPEN and Registration to open in early January 2025.

 ScienceLIVE scopes.jpg

ScienceLIVE Educational Outreach Program

ScienceLIVE is an educational science outreach program for Worcester area middle schools. We provide opportunities for students to engage with our diverse postdoctoral and graduate student trainees through interactive, exciting virtual and hands-on STEM activities.

 SupportUs.jpg

Support Our Next Breakthrough

For decades, scientists at UMass Chan have been pioneers in RNA biology and leading innovators in the development of information-based therapeutics: cutting-edge therapeutic tools that leverage our understanding of the human genome in ways that are revolutionizing how we treat disease. With your support, we are poised to unleash their power, and change the world for the better.
 wolfe-watts-sontheimer-in-story-photo--660-1.webp

UMass Chan scientists receive $2.3 million from Rett Syndrome Research Trust for research

Erik Sontheimer, PhD, the Pillar Chair in Biomedical Research and professor of RNA therapeutics; Jonathan Watts, PhD, professor of RNA therapeutics; and Scot Wolfe, PhD, professor of molecular, cell & cancer biology, were awarded $2.3 million in new funding from the Rett Syndrome Research Trust to utilize base-editing and prime-editing technologies to correct mutations in MECP2.

Current treatments for Rett syndrome symptoms are palliative, but gene therapy clinical trials aimed at addressing the disease’s underlying causes are underway.  

“I am cautiously optimistic there’s a good chance that these gene therapy approaches are going to be successful at making some difference. The editing approaches we’re working on have the chance to change disease outcomes even more profoundly, and perhaps enable patients to get much closer to normalcy, especially if the disease can be caught earlier,” Dr. Watts said.  

Read more››


   More Watts Group Research

 

 

Journey of a Nobel Discovery

Presented by ICBA, BBC StoryWorks

Meet Craig Mello, part of the RTI at UMass Chan, who was awarded the 2006 Nobel Prize in Physiology or Medicine, with Andrew Z. Fire, for the discovery of RNA interference. The discovery of RNAi has given scientists unprecedented opportunities to develop new life-saving therapies and advance our basic understanding of biology.